IP Library Granted Patent US 9,857,364
Granted Patent B2
US 9,857,364 · App. 14/359,957 · Granted Jan 2, 2018

Method for detection of binding

Inventors: Tanja Jarhede (Uppsala, SE); Anita Larsson (Uppsala, SE)
Assignee: GE Healthcare Bio-Sciences AB
G01N33/54306G01N33/54373G01N33/54393G01N21/553
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,857,364
App. No.
14/359,957
Granted
Jan 2, 2018
Kind
B2
Abstract

The present invention relates to a method for detection of binding or interaction events between a binding agent and its corresponding analyte (such as an antibody and an antigen) in which a signal is detected which is substantially more amplified and thus easier to detect than in prior art systems. The method comprises simultaneous but separate addition of a first enhancement reagent having affinity for said analyte and a second enhancement reagent having affinity for the first enhancement reagent wherein the first enhancement reagent binds to the analyte and the second enhancement reagent binds to the first enhancement reagent, and, wherein the first and second enhancement reagents have more than one binding site so that they are able to bind to each other to thereby amplify a detectable signal from the binding event.

Claims (14)

1. A method for detecting with a biosensor a binding event between a binding agent on a solid support and an analyte, comprising:

simultaneously and separately adding a first enhancement reagent having affinity for said analyte and a second enhancement reagent having affinity for said first enhancement reagent, wherein the first enhancement reagent binds to the analyte and the second affinity agent binds to the first enhancement reagent, and wherein the first and second enhancement reagents have more than one binding site so that they are also able to bind to each other to thereby amplify a detectable signal generated by the binding event; and

detecting, using a label-free detection technique, the detectable signal with the biosensor.

2. The method of claim 1 , wherein the first and second enhancement reagents are simultaneously injected to the solid support via a flow channel system.

3. The method of claim 2 , wherein the first and second enhancement reagents have undergone a substantially complete mixing before entering a detection area of a biosensor surface.

4. The method of claim 1 , comprising addition of the analyte before addition of the enhancement reagents.

5. The method of claim 1 , comprising addition of the analyte together with the second enhancement reagent.

6. The method of claim 1 , wherein the binding agent is a monoclonal antibody directed against the analyte; the first enhancement reagent is a polyclonal antibody with binding sites for the analyte and the second enhancement reagent; and the second enhancement reagent is a polyclonal antibody directed against the first enhancement reagent.

7. The method of claim 1 , wherein the analyte is present in a concentration of 1.56 nm/ml to 50 ng/ml.

8. The method of claim 1 , wherein the label-free detection technique comprises evanescent wave sensing.

9. The method of claim 1 , wherein the detection is performed in a flow cell.

10. The method of claim 9 , wherein the flow cell comprises a detection area with the binding agent, and an inlet which via a junction is connected to first and second conduits, wherein the binding agent is an immobilized ligand, and wherein the first and second enhancement reagents mixing comprises flowing the reagent solutions in respective conduits so that the two fluids mix at the junction of the flow cell inlet conduit and the mixed fluids pass through the flow cell over the detection area.

11. The method of claim 10 , wherein the mixed fluids reach the detection area when a substantially complete mixing has occurred.

12. The method of claim 1 , wherein the label-free detection technique comprises surface plasmon resonance (SPR).

Assignments (2)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIO-SCIENCES AB
To: CYTIVA SWEDEN AB
Reel/Frame 054262/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2014
From: JARHEDE, TANJA; LARSSON, ANITA
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 032947/0047 →
Priority Claims (1)
SE 1151291 · Dec 30, 2011 · national
Continuity (1)
Related Publication 20140322826A1 · Oct 30, 2014